Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: Post hoc analysis of the VIEW studies
Acta Ophthalmologica Dec 09, 2018
Lanzetta P, et al. - Researchers aimed at identifying the factors that could predict the response to anti-vascular endothelial growth factor (VEGF) therapy in patients with neovascular (wet) age-related macular degeneration (nAMD). They performed this retrospective, post hoc analysis of VIEW 1/2. Patients were randomized 1:1:1:1 to 0.5 mg intravitreal aflibercept (IVT-AFL) injection every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after an initial three injections at weeks 0, 4 and 8 or 0.5 mg intravitreal ranibizumab every 4 weeks (0.5q4). They noted greater vision gains in association with younger age, lower visual acuity (VA) and smaller choroidal neovascularization (CNV) size at baseline over 52 weeks. While best-corrected VA 20/40 or better were more frequently observed in relation with younger age, higher VA and smaller CNV size at treatment start after a year's treatment. This highlights early anti-VEGF treatment as beneficial for these patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries